Tirzepatide

Tirzepatide is a long synthetic peptide engineered for agonist activity at both the GIP and GLP-1 receptors. That dual-agonist design distinguishes it from selective GLP-1 agonists such as semaglutide and from triple-agonist frameworks such as retatrutide.

At roughly 4814 g/mol it sits at the upper end of catalog peptide masses, with the same analytical implications as other large incretin peptides: shallower gradients, aggregation risk and greater value in mass confirmation.

Public interest in incretin peptides is high. VaultLabs states plainly that research material is not a medicine and is not supplied for human use.

Clinical-trial literature compares tirzepatide with selective GLP-1 agonists and reports metabolic endpoints for pharmaceutical products. That literature describes regulated medicines, not laboratory reference powder.

For a purchasing laboratory the relevant uses are analytical: method development, reference standards and comparative receptor-pharmacology work in vitro.

Release is by HPLC with lot-linked certification. Reconstitute gently without vigorous agitation, inspect for haze, and limit freeze-thaw cycles.

Store sealed at 2–8 °C. Tirzepatide research material is not an approved medicine and is not for human use.

VaultLabs Tirzepatide 30mg is laboratory reference material only. Orders are accepted against a research-use declaration.

Do not conflate this SKU with pharmaceutical tirzepatide products or with Semaglutide / Retatrutide catalog lines.

Large incretin peptides adsorb to some plastics and aggregate when shaken. Method development should specify vessel type, diluent and hold time rather than assuming short-peptide handling SOPs remain valid without verification.

Comparative work against semaglutide or retatrutide must cite distinct certificates for each SKU. Shared freezer space is fine; shared lot documentation is not.

VaultLabs retains the research-use declaration with the order record. Institutional buyers remain responsible for their own approvals, import classifications and internal controls applicable in the United Arab Emirates.

This monograph is a reference article for laboratory purchasers and documentation staff. It summarises chemical identity, literature context and handling constraints that affect analytical work. It is not a protocol, not a dosing guide and not a substitute for institutional SOP review.

Where pharmaceutical or clinical papers are cited, they are included only to anchor compound identity and regulatory status. They do not authorise human use of VaultLabs research material, and they do not convert a lyophilised reference vial into a finished medicine.

If a certificate, label and monograph appear to disagree, stop and query support with the lot number before the material enters an experiment. Lot-linked certificates override general catalog copy for the specific unit in hand.

VaultLabs updates monographs when catalog strengths or documentation practice change. The updatedAt field marks the editorial revision date for this article, not the manufacture date of any particular lot.

All VaultLabs materials named here remain research-use-only: not for human consumption, not for medical use, and not for personal application under any reading of the surrounding literature.

Dual incretin receptor pharmacology

Comparative GLP-1 / GIP agonist assays

Analytical characterisation of large incretin peptides

2–8 °C (lyophilized, sealed)

2–8 °C sealed; temperature-aware UAE dispatch recommended.

Large incretin peptides are aggregation-prone — gentle reconstitution, minimal agitation, and limited freeze-thaw cycles.